VolitionRX Limited

Good day, ladies and gentlemen. Thank you for standing by. Welcome to VolitionRx Limited's third quarter 2024 earnings conference call. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the conference call will be opened for questions. If you have a question, please press the star key followed by the number one on your touchstone phone. If you would like to withdraw your question, please press the star key followed by the number two. If you're using speaker equipment, please lift the handset before making your selections. This conference is being recorded today, November 15th, 2024. I would now like to turn the conference call over to Louise Bachelet, Group Chief Marketing and Communications Officer. Please go ahead.

Thank you and welcome everyone to today's earnings conference call for VolitionRx Limited. Before we begin, I'd like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our beliefs as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties and assumptions. Actual future results may vary significantly based on a number of factors that may cause the actual results or events to be materially different from future results, performance or achievements expressed or implied by these statements. We have identified various risk factors associated with our operations in our most recent annual report on Form 10-K, quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission. We do not undertake an obligation to update any forward-looking statements made during the course of this call. Dr. Tom Butera, Chief Executive Officer of our Volition Veterinary subsidiary, will open the call today, providing the key highlights for new QVet for the third quarter and indeed the year to date. He will then pass over to Dr. Andrew Retter, Chief Medical Officer, who will cover off some significant progress from the Innovation Lab R&D and clinical team. Chief Financial Officer Terry Cuse will then provide the financial report and Cameron Reynolds, President and Group Chief Executive Officer, will wrap up with a summary and look ahead to upcoming milestones. We will then open the conference call to a question and answer session. And with that, I'll turn the call over to Tom.

Thanks, Lou. And thank you, everyone, for joining Volition's third quarter. 2024 earnings call today. As Cameron always says, we appreciate your time given the busy earnings season. November is Pet Cancer Awareness Month, and so I'm especially honored to open the call today. I'm delighted to report that we have now sold over 110,000 new cuVet cancer tests in the first three quarters of 2024 versus 58,000 in the whole of last year, 2023. You have heard me say it many times. Our test is a simple, affordable, easy to use blood screening test. It can be integrated easily into preventive care programs and used alongside other routine blood work during regular wellness visits. By detecting cancer early, we can help to improve and extend the lives of millions of dogs and keep that special member of the family with us longer. Our new QVET cancer test is now available in 17 countries and counting. Our revenue growth is accelerating quarter on quarter. Year-to-date revenue growth is 100%, while in this quarter, revenue was up 307%, each versus the same periods of 2023. Year-to-date revenue of our veterinary kits and key components is approximately $730,000. We don't have time to discuss each and every distributor of our NUQ Vet Cancer Test, but this quarter I'd like to specifically mention three. First, Fujifilm Vet Systems. Wow. Fuji launched nationwide this quarter in July, and I am delighted to say that already almost 10% of their veterinarians have ordered the NUQ test, a very rapid market penetration. Thanks so much to the Fuji team, and my colleague in particular, Jasmine Quay, for their dedicated efforts in Japan. Next up, VetLab Poland. Again, a fairly recent addition to our stable, also launching the test this past July. They have made a great impact in the local market, which includes a few countries they also service around Poland. Dr. Heather Wilson-Robles, our Volition Vet Chief Medical Officer, has been invited to speak next week on NewQVet at Poland's largest veterinary conference, where many veterinarians will be in attendance. VetLab's website and marketing efforts are top-notch, so many kudos and congratulations to them on their hard work. And last but not least, Heska, which is now a Mars Antec company, has worldwide distribution channels in numerous markets under the new brand of Antec. Antec has made significant progress introducing NUQ Vet on the Element I Plus in-hospital instrument around the world. It is now available in 15 countries and counting. We have received some fantastic testimonials, and given November is Pet Cancer Awareness Month, Antec has generated a great deal of activity promoting NUQ's early cancer screening test. In particular, I'd like to highlight an upcoming Antec webinar with Dr. Sue Ettinger, a longtime world-renowned veterinary oncologist and strong advocate of our new QVET cancer test. Dr. Ettinger is now the proud user of the LMNI Plus in her own veterinary hospital. I was delighted to join Antec's chief medical officer, Dr. James Barr, and other members of the Antec team this week at some launch events in the UK, including multiple presentations of NewQ at the London Vet Show yesterday. It's a testament to our close collaboration and was a real honor, so thank you to the Antec team. I have the pleasure now of handing over to Dr. Andrew Retter, Chief Medical Officer on our human side of the business. But before I do, I'd like to thank Andy for joining me and meeting with the Antec team yesterday. Here at Volition, we are in a pretty unique position when it comes to the critically important topic of One Medicine, which connects and shares veterinary and human clinical advancements for the betterment of the human and animal world. It was really terrific for Andy to share insights from our human research with Dr. James Barr and to discuss the ways in which discoveries across our human and veterinary pillars, not only for cancer, but including diseases such as sepsis, might help both companies in their missions to help improve and save lives. So thanks, Andy, for your time. And now I'll turn the call over to you.